AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31302052 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with SPRM score above median (n = 558)
Number of subjects: 1116
Study 31302052 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation in patients with SPRM score below median (n = 558)
Number of subjects: 1116
Study 31302052 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with SHFM score above median
Number of subjects: 1116
Study 31302052 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation in patients with SHFM score below median
Number of subjects: 1116
Study 31302052 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in 177 patients with upper SPRM/upper SHFM
Number of subjects: 1116
Study 31302052 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation in 381 patients with lower SPRM/upper SHFM
Number of subjects: 1116
Study 27835770 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball exercise
Number of subjects: 61
Study 27835770 — intervention group
Group type: COMPARATOR
Intervention: Functional exercise
Number of subjects: 61
Study 26066335 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg daily for 6 weeks)
Number of subjects: 108
Study 26066335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soybean powder)
Number of subjects: 108
Study 24476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 50 mg/kg daily for 8 weeks in DM
Number of subjects: 0
Study 24476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg daily for 12 weeks in obese humans
Number of subjects: 0
Study 24476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 750 mg daily for 12 weeks in obese humans
Number of subjects: 0
Study 22503032 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 401
Study 22503032 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 401
Study 19364302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily
Number of subjects: 17
Study 19364302 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg once daily
Number of subjects: 17
Study 19364302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily plus Metformin 1000 mg once daily
Number of subjects: 17
Study 17694726 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 593
Study 17694726 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 593
Study 17694726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 15580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Rapport and Partnership Building
Number of subjects: 140
Study 15580724 — intervention group
Group type: COMPARATOR
Intervention: Information Giving
Number of subjects: 140
Study 15580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parent socioeconomic status
Number of subjects: 140
Study 11729705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 0
Study 11729705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline
Number of subjects: 0
Study 9364979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 9364979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate
Number of subjects: 0
Study 1409483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography adherence
Number of subjects: 0
Study 1409483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap test frequency
Number of subjects: 0
Study 1409483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical breast exam frequency
Number of subjects: 0
Study 1409483 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination frequency
Number of subjects: 0
Study 4028807 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release tablet formulation of 300 mg fentiazac, given once daily
Number of subjects: 60
Study 4028807 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet formulations of 100 mg, given 4-times daily
Number of subjects: 60
Study 4028807 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet formulations of 200 mg, given twice daily
Number of subjects: 60
Study 30758220 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt list and educational video intervention
Number of subjects: 359
Study 30758220 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 359
Study 29567321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 48
Study 29567321 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 48
Study 26851696 — intervention group
Group type: COMPARATOR
Intervention: Bihemispheric tDCS (dual)
Number of subjects: 24
Study 26851696 — intervention group
Group type: COMPARATOR
Intervention: Unihemispheric anodal tDCS
Number of subjects: 24
Study 26851696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Number of subjects: 24
Study 24475777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 143
Study 24475777 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod 1.25 mg or 0.5 mg (switched from placebo)
Number of subjects: 143
Study 24475777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (continuously treated)
Number of subjects: 143
Study 24475777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (in AQP4 antibody-positive patients)
Number of subjects: 143
Study 22268125 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim (1,350 mg/day)
Number of subjects: 30
Study 22268125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22268125 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim
Number of subjects: 30
Study 20852750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg tablet; LPH® S.C. LaborMed Pharma S.A. Romania)
Number of subjects: 12
Study 20852750 — intervention group
Group type: COMPARATOR
Intervention: Zantac® (300 mg tablet; GlaxoSmithKline, Austria)
Number of subjects: 12
Study 18180567 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-hyaluronate (Orthovisc, n=38)
Number of subjects: 77
Study 18180567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (Synvisc, n=18)
Number of subjects: 77
Study 18180567 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcal HA (Adant, n=21)
Number of subjects: 77
Study 16303007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg/day
Number of subjects: 1652
Study 16303007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1652
Study 12512229 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 17
Study 12512229 — intervention group
Group type: COMPARATOR
Intervention: Control (no eicosapentaenoic acid)
Number of subjects: 17
Study 9809087 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone/fentanyl (Group 1: n = 16)
Number of subjects: 32
Study 9809087 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl (Group 2: n = 16)
Number of subjects: 32
Study 9809087 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 32
Study 9809087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthesia types (isoflurane and propofol)
Number of subjects: 32
Study 7695972 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL2/5‐FU/LV
Number of subjects: 135
Study 7695972 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV
Number of subjects: 135
Study 2316824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dp-group (aluminium-hydroxide added to Dp-extract)
Number of subjects: 37
Study 2316824 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-Dp-group (allergenicity reduced by coupling to mPEG)
Number of subjects: 37
Study 2316824 — intervention group
Group type: COMPARATOR
Intervention: Dp-group
Number of subjects: 37
Study 2316824 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-Dp-group
Number of subjects: 37
Study 7468956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine combined with halothane
Number of subjects: 48
Study 7468956 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 48
Study 7468956 — intervention group
Group type: COMPARATOR
Intervention: Ethrane
Number of subjects: 48
Study 7468956 — intervention group
Group type: COMPARATOR
Intervention: Halothane without ketamine
Number of subjects: 48
Study 7468956 — intervention group
Group type: COMPARATOR
Intervention: Ethrane without ketamine
Number of subjects: 48
Study 31760911 — intervention group
Group type: EXPERIMENTAL
Intervention: Age- and dementia-relevant jury instructions
Number of subjects: 391
Study 31760911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock juror gender
Number of subjects: 391
Study 31760911 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit agism among jurors
Number of subjects: 391
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (72%)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue therapy (70%)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation (35%)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Back problems (49%, 95% CI 44 to 56)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck problems (15%, 95% CI 13 to 18)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance/preventive care (0.86%, 95% CI 0.2 to 3.9)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-musculoskeletal problems (1.3%, 95% CI 0.7 to 2.3)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from other patients (39.4%)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from physicians (6.8%)
Number of subjects: 3523
Study 31455707 — intervention group
Group type: EXPERIMENTAL
Intervention: Out of pocket or extended health insurance payments (68%)
Number of subjects: 3523
Study 28450313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 240
Study 28450313 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 240
Study 25967725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose selective spinal anesthesia with 5 mg bupivacaine + single‐shot femoral block with 0.25% bupivacaine
Number of subjects: 52
Study 25967725 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose selective spinal anesthesia with 10 mg bupivacaine
Number of subjects: 52
Study 24045793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (as the best performer ingredient from Study 1)
Number of subjects: 29
Study 24045793 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 different food ingredients (including coffee, tea, milk, curcumin, potato protease inhibitor)
Number of subjects: 29
Study 21863030 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (320 mg day(-1))
Number of subjects: 204
Study 21863030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 21863030 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 204
Study 19549707 — intervention group
Group type: EXPERIMENTAL
Intervention: CET-CF (cetuximab plus cisplatin-5-fluorouracil); cetuximab 400 mg/m² initial dose followed by 250 mg/m² weekly, cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Number of subjects: 62
Study 19549707 — intervention group
Group type: COMPARATOR
Intervention: CF (cisplatin-5-fluorouracil); cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Number of subjects: 62
Study 17547268 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of hot and cold beverages; waiting at least 30 minutes after drinking
Number of subjects: 0
Study 17547268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradypnea
Number of subjects: 0
Study 14715393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600/650 mg
Number of subjects: 0
Study 14715393 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 600/650 mg
Number of subjects: 0
Study 14715393 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0
Study 14715393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 14715393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11887670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental appliance treatment for headache patients
Number of subjects: 0
Study 9597297 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to imbibe
Number of subjects: 128
Study 9597297 — intervention group
Group type: COMPARATOR
Intervention: Nonorganic failure to thrive
Number of subjects: 128
Study 9597297 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 128
Study 9597297 — intervention group
Group type: COMPARATOR
Intervention: Diseased controls
Number of subjects: 128
Study 7870637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy, fruit- and vegetable-enriched prudent diet (Group A)
Number of subjects: 406
Study 7870637 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 406
Study 3170120 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 46
Study 3170120 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 46
Study 30936104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1g/24hrs)
Number of subjects: 22
Study 30936104 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1g/8hrs)
Number of subjects: 22
Study 28427955 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICES Plus
Number of subjects: 261
Study 28427955 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice
Number of subjects: 261
Study 25261004 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) cardiac troponin-T testing
Number of subjects: 452
Study 25261004 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based cardiac troponin-T testing
Number of subjects: 452
Study 23858436 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition C (4-year-old child)
Number of subjects: 30
Study 23858436 — intervention group
Group type: COMPARATOR
Intervention: Condition A (adult body)
Number of subjects: 30
Study 23858436 — intervention group
Group type: COMPARATOR
Intervention: Visuomotor asynchrony (Exp. 2)
Number of subjects: 30
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 32
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab combined with oral CYC
Number of subjects: 32
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Other agents including biological agents
Number of subjects: 32
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction-refractory disease characteristics
Number of subjects: 32
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction-refractory disease mortality
Number of subjects: 32
Study 20643762 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive alveolar haemorrhage
Number of subjects: 32
Study 18419216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy transurethral microwave thermotherapy (HE-TUMT) with CoreTherm device
Number of subjects: 458
Study 18419216 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 458
Study 15937580 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Eastern women with PCOS
Number of subjects: 92
Study 15937580 — intervention group
Group type: COMPARATOR
Intervention: Western European women with PCOS
Number of subjects: 92
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal injection
Number of subjects: 1023
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic velocity
Number of subjects: 1023
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigidometer values
Number of subjects: 1023
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic velocity
Number of subjects: 1023
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index
Number of subjects: 1023
Study 12946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes, control of diabetes, diabetes-related complications
Number of subjects: 1023
Study 10955702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10955702 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 8
Study 8899091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rINF-beta ser (6 x 10(6) U/dose, three times a week for 6 months)
Number of subjects: 20
Study 8899091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rINF-beta ser (30 x 10(6) U/dose, three times a week for 6 months)
Number of subjects: 20
Study 8899091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low-dose and high-dose rINF-beta ser
Number of subjects: 20
Study 1999536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured skin equivalents
Number of subjects: 5
Study 1999536 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness skin punch grafts
Number of subjects: 5
Study 6190489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 50
Study 6190489 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 50
Study 6190489 — intervention group
Group type: EXPERIMENTAL
Intervention: Duador
Number of subjects: 50
Study 31945691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral bone conduction devices (BCDs)
Number of subjects: 0
Study 31945691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral bone conduction devices (BCDs)
Number of subjects: 0
Study 31945691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral bone conduction devices (BCDs) in simulated bilateral conductive hearing loss
Number of subjects: 0
Study 31945691 — intervention group
Group type: COMPARATOR
Intervention: Normal open ear (control)
Number of subjects: 0
Study 31324402 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic produce
Number of subjects: 20
Study 31324402 — intervention group
Group type: COMPARATOR
Intervention: Conventional produce
Number of subjects: 20
Study 30431588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 61
Study 30431588 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 61
Study 27126292 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Excursion Test (HET)
Number of subjects: 100
Study 27126292 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Excursion Test (TET)
Number of subjects: 100
Study 25148243 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (20-50 mg BID)
Number of subjects: 445
Study 25148243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 21913966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial cardiovascular risk intervention
Number of subjects: 345
Study 21913966 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 345
Study 20225658 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 32
Study 20225658 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 32
Study 20225658 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 17106430 — intervention group
Group type: EXPERIMENTAL
Intervention: Transiently evoked otoacoustic emissions
Number of subjects: 24
Study 17106430 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 age-matched healthy volunteers)
Number of subjects: 24
Study 15696445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) categorized by estimated Glomerular Filtration Rate (eGFR)
Number of subjects: 1015
Study 15696445 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 1015
Study 12425155 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 0
Study 12425155 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 0
Study 10588630 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized CXR using the interface
Number of subjects: 25
Study 10588630 — intervention group
Group type: COMPARATOR
Intervention: Conventional CXR techniques
Number of subjects: 25
Study 7598919 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous monitoring
Number of subjects: 104
Study 7598919 — intervention group
Group type: COMPARATOR
Intervention: No central venous monitoring
Number of subjects: 104
Study 2180557 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol mouthwash (20 mg)
Number of subjects: 77
Study 2180557 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 77
Study 7462462 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated vowels
Number of subjects: 0
Study 7462462 — intervention group
Group type: COMPARATOR
Intervention: Vowels in consonantal context
Number of subjects: 0
Study 31888605 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding low back pain booklet
Number of subjects: 136
Study 28682100 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevance interventions (specific types not detailed)
Number of subjects: 1916
Study 28682100 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 1916
Study 26060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging interviews (administered by human interviewers)
Number of subjects: 634
Study 26060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging interviews (administered by automated systems)
Number of subjects: 634
Study 26060991 — intervention group
Group type: COMPARATOR
Intervention: Voice interviews (administered by human interviewers)
Number of subjects: 634